Key result
Severe liver fibrosis in patients with MAFLD was associated with a significantly higher rate of atrial fibrillation recurrence following catheter ablation compared to MAFLD patients without fibrosis (HR 5.345).
Why the study?
Epidemiological studies suggest an association between MAFLD and AF incidence, but the pathogenesis leading to AF in the context of MAFLD remains unclear.
Does severe liver fibrosis in MAFLD patients increase adverse atrial remodeling and AF recurrence following catheter ablation?
Population
Patients undergoing AF ablation and patients undergoing cardiac surgery
Comparison
MAFLD across liver fibrosis severity stages vs no MAFLD
Design
Two-cohort study
Authors
Loading...
Severe MAFLD fibrosis was associated with higher post-ablation AF recurrence; this observational link leaves open whether fibrosis screening should guide ablation decisions.
Cohort (n=245)
No
Does severe liver fibrosis in MAFLD patients increase adverse atrial remodeling and AF recurrence following catheter ablation?
Hazard Ratio: 5.345 (95% CI 1.335–21.4)
Absolute Event Rate: 77% vs 17.5%
p-value: p=0.0179
High liver fibrosis scores in patients with MAFLD are associated with adverse left atrial remodeling and a significantly increased risk of AF recurrence following catheter ablation.
Decoin et al. (2022) conducted a cohort in Atrial Fibrillation and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) (n=245). Severe liver fibrosis in MAFLD (NAFLD Fibrosis Score ≥ 0.675) vs. MAFLD without severe fibrosis (NAFLD Fibrosis Score < -1.455) was evaluated on Atrial fibrillation recurrence (HR 5.345, 95% CI 1.335-21.40, p=0.0179). Severe liver fibrosis in patients with MAFLD was associated with a significantly higher rate of atrial fibrillation recurrence following catheter ablation compared to MAFLD patients without fibrosis (HR 5.345).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: